Key result
BGP-15 treatment considerably enhanced diastolic function by affecting the SERCA/phospholamban pathway in Goto-Kakizaki rats, without significantly altering glucose homeostasis or vascular status.
Why the study?
To investigate whether the insulin-sensitizer BGP-15 exerts additive cardiovascular effects compared to metformin or pioglitazone in a diabetic cardiomyopathy rat model.
Does BGP-15 improve diastolic function in a rat model of diabetic cardiomyopathy compared to metformin or pioglitazone?
Does BGP-15 improve diastolic function in a rat model of diabetic cardiomyopathy compared to metformin or pioglitazone?
In a rat model of diabetic cardiomyopathy, BGP-15 enhanced diastolic function by affecting the SERCA/phospholamban pathway without significantly altering glucose homeostasis.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for BGP-15 in diabetic cardiomyopathy; human trials needed before clinical consideration.
Bombicz et al. (2019) studied Diabetic cardiomyopathy. BGP-15 vs. Untreated GotoK rats, metformin, and pioglitazone was evaluated on Diastolic parameters (e'/a', E/e', LAP, E and A wave) and Tei-index. BGP-15 treatment considerably enhanced diastolic function by affecting the SERCA/phospholamban pathway in Goto-Kakizaki rats, without significantly altering glucose homeostasis or vascular status.